Page 161 – New meningococcal vaccines and immunisation schedules: successes and challenges

Dr Chris Bayliss, Dr Luke Green and Dr Caroline Cayrou


  1. Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. The Lancet 2016;388:2775–2782.
  2. Biagini M, Spinsanti M, De Angelis G, Tomei S, Ferlenghi I, Scarselli M et al. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci USA 2016;113:2714–2719.
  3. Cayrou C, Akinduko AA, Mirkes EM, Lucidarme J, Clark SA, Green LR et al. Clustered intergenic region sequences as predictors of factor H Binding Protein expression patterns and for assessing Neisseria meningitidis strain coverage by meningococcal vaccines. PLoS ONE 2018;13:e0197186.
  4. Turner DP, Oldfield NJ, Bayliss CD. University vaccine campaign increases meningococcal ACWY vaccine coverage. Public Health 2017;145:1–3.
  5. Oldfield NJ, Cayrou C, AlJannat MAK, Al-Rubaiawi AAA, Green LR, Dada S et al. Rise in Group W Meningococcal Carriage in University Students, United Kingdom. Emerg Infect Dis 2017;23:1009–1011.